Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 700-838 West Hasting Street VANCOUVER BC V6C 0A6 |
Tel: | N/A |
Website: | https://www.novamentis.ca |
IR: | See website |
Key People | ||
Derek Ivany Executive Chairman of the Board | William Rascan President, Chief Executive Officer, Director | Rebecca Hudson Chief Financial Officer |
Jacqueline Mcconnell Chief Operating Officer, Director | Stephen Glazer Chief Science Officer, Director |
Business Overview |
Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc. |
Financial Overview |
For the fiscal year ended 31 December 2023, Nova Mentis Life Science Corp revenues was not reported. Net loss decreased 50% to C$1.2M. Lower net loss reflects Consulting fees decrease of 40% to C$470K (expense), Office and general decrease of 62% to C$120K (expense), Share-based payments decrease of 17% to C$273K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.02 to -C$0.01. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $2.21M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$1.26M as of Dec 31, 2023 |
Net annual income (TTM): | -$1.22M as of Dec 31, 2023 |
Free cash flow (TTM): | -$0.28M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 148,168,660 as of Jan 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |